Question · Q3 2025
Willan asked about Mirion's overall pricing power, specifically whether it is trending differently between the nuclear safety and medical segments.
Answer
Brian Schopfer, EVP, CFO, and Medical Group President, Mirion, reported a $2 million positive price-cost impact in the quarter, attributing it to internal investments in pricing methodologies. He noted a less aggressive pricing approach on the U.S. medical side compared to the nuclear segment, confident in the strong moats around Mirion's product portfolio.